Abstract. Sprouty2 (Spry2) was identified recently as a tumor suppressor gene in cancer cells which inhibits the activation of receptor tyrosine kinases (RTKs). The present study explored the effect of Spry2 in colon cancer cells in order to assess its potential use in the treatment of colon cancer. Expression of Spry2 inhibited the growth of a colon cancer cell line, HCT116, and induced sensitization to fluorouracil (5-FU) and metformin. Spry2 promoted apoptosis of cancer cells in association with activation of the phosphatase and tensin homolog deleted on chromosome 10 (PTEN) pathway and the blockade of Ras-Raf-Erk signaling. Treatment of Spry2-HCT116 cells with metformin resulted in a more prominent effect on the inhibition of cell migration. Inhibition of microRNA-21 (mir-21) induced upregulation of Spry2 and PTEN which underscores the importance of mir-21 in Spry2-associated tumorigenesis of the colon. These results point toward a potential strategy for colon cancer treatment worthy of further investigation.

Introduction

Growth factor signaling by receptor tyrosine kinases (RTKs) regulates several important cellular functions in tumor cells, such as proliferation and invasion. A negative feedback mechanism is one of the mechanisms that provide effective control via modulation of the activated RTKs pathway. Sprouty (Spry) was originally described in Drosophila as an antagonist to Breathless, the insect equivalent of fibroblast growth factor (FGF) receptor, since the loss of function of Spry led to overactive FGF signaling, hence, an excessive branching network, while forced expression of Spry blocked tracheal branching (1). Subsequent studies have demonstrated that Spry can also inhibit the Drosophila epithelial growth factor receptor (EGFR), as well as other RTKs (2-4).

Mammals have at least four isoforms of Spry protein (Spry1-4). All Spry genes have a highly conserved C-terminal cysteine-rich domain that is important for the membrane localization of Spry family members (5,6). The N-terminal domain of Spry family members is less well conserved (25-37%) and may impart unique functions to individual family members. The N-terminal domain of Spry2 binds to c-Cbl, a ring-finger domain containing protein, and one involved in targeting the EGF receptor (7-10). Within the Spry family, Spry2 exhibits the highest level of homology to the ancestral gene. Regarding cellular functions, Spry2 owes its ability to its inhibition of Akt and Erk activation induced by some, but not all RTKs (11). Previous reports have shown that Spry2 was de-regulated in human cancer, including breast, prostate and liver cancer (12-14). Overexpression of Spry2 in osteosarcoma cancer cells inhibits proliferation and migration, implying a novel strategy in cancer treatment (15).

The first identified biochemical hallmark of tumor cells was a shift in glucose metabolism from oxidative phosphoryla-
tion to aerobic glycolysis. In the 1920s, Warburg proposed a
defect in the cellular energy of tumor cells, utilizing glycolysis
instead of mitochondrial oxidative phosphorylation for glucose
metabolism, even in oxygen-rich conditions (the ‘Warburg
effect’) (16). The adenosine monophosphate (AMP)-activated
protein kinase (AMPK), a master metabolic regulator, has
been connected to several human tumor suppressors. It is
highly conserved as a heterotrimer, and composed of α
and β and γ regulatory subunits. AMPK is activated under conditions of decreased intracellular
ATP and increased intracellular AMP, such as nutrient deprevation or hypoxia. While activated, AMPK increases catabolic
ATP-generating processes such as fatty-acid oxidation and
inhibits ATP-consuming biosynthetic processes such as protein,
cholesterol and fatty-acid synthesis (17). In mammalian
systems, the dominant upstream kinase responsible for
activating AMPK is a novel kinase named LKB1, which had
been previously identified as the tumor suppressor mutated
in the rare autosomal dominant Peutz-Jeghers syndrome (18).
Patients with Peutz-Jeghers syndrome universally develop
gastrointestinal polyps and are predisposed to several types of
cancer, especially colon cancer at an early age. Genetic deple-
tion of LKB1 in mouse embryonic fibroblasts (MEFs) results
in a loss of AMPK activation following energy stresses that
raise AMP (19). Metformin, a biguanide commonly used in the
treatment of type 2 diabetes mellitus, recently demonstrated the ability to inhibit the breast cancer growth through
activation of AMPK and inactivation of a mammalian target
of rapamycin (mTOR) and S6 kinase (20,21). In p53 (-/-) colon
cancer cells, metformin was found to increase cell apoptosis,
but to activate autophagy in p53 (+/+ ) cells (22). Another report
showed that 5-aminimidazole-4-carboxamide ribonucleoside
(AICAR), a pharmacologic activator of AMPK, enhanced
apoptosis of wild-type p53 colon cancer cells co-treated with
 tumor necrosis factor (TNF)-related apoptosis-inducing ligand
(TRAIL) (23). It is critical to explore the therapeutic strategy of
metformin and its link with other treatment options in colon
cancer.

Materials and methods

Cell culture. The human colon cancer cell line, HCT116, was
obtained from the American Type Culture Collection and
cultured in Dulbecco’s modified Eagle’s medium/F12 with
10% fetal bovine serum.

Reagents. Fluourouracil (5-FU) and methylthiazolidinphenyl-
tetrazolium bromide (MTT) powder were purchased from Sigma-Aldrich (USA). Metformin was obtained from Alexis
(Germany) and was dissolved in water. Anti-phosphorylated-AMPK, anti-phosphorylated Akt, and anti-total Akt were from
Cell Signaling (USA). Anti-PTEN was obtained from Santa
Cruz Biotechnology, Inc., and anti-α-tubulin was purchased
from Sigma-Aldrich. Horseradish peroxidase-conjugated anti-
rabbit IgG and anti-mouse IgG were from Pierce (USA). The
Annexin V kit and the enhanced chemiluminescent (ECL)
reagents were from Roche Diagnostic (USA). Anti-poly (ADP-ribose)
polymerase (PARP) was from BD Pharmingen (USA) and
anti-BCL2 was from Transduction Laboratories (USA). Anti-
Spry2 was obtained from Upstate Biotechnology (USA).

Constructs and transfection. Human Spry2 full-length cDNA
was inserted in a pEGFP-N3 (Spry2-GFP) vector (15) as a kind
gift from Vande Woude, Van Andel Research Institute. HCT116
cells were transfected with Spry2-GFP expression plasmid
(Spry2-HCT116) and Lipofectamine (Invitrogen, USA), as
described in the manufacturer’s standard procedure. HCT116
cells transfected with pEGFP-N3 empty vector were regarded as
vector-HCT116 cells.

Cytotoxicity assay. The cytotoxicity of cells was assessed by the
MTT assay. In brief, HCT116 colon cancer cells were trans-
fected with Spry2-GFP plasmid or vector only plasmid, using
the Lipofectamine method. Forty-eight hours after transfec-
tion, Spry2-HCT116 and vector-HCT116 were cultured in a
96-well plate (Corning, Inc., USA) at a density of 4,000 cells/
well in DMEM/F12 with 10% FBS (controlled medium). After
24 h incubation, 25 µM of 5-FU or 20 mM of metformin
was added to DMEM/F12 with 10% FBS, in a total volume
of 200 µl/well, to replace the original DMEM/F12. After
96 h, 20 µl of 5 mg/ml MTT solution was added to each well.
Plates were incubated in the dark for 2 h and then the crystal
was eluted with 100 µl DMSO after removal of the culture
medium and the MTT solution. The absorbance was measured
at 570 nm using a microtiter plate reader (MRX Revelation,
Dynex, USA).

Annexin V staining, propidium iodide staining and flow cytom-
etry. HCT116 cells were transfected with Spry2-GFP or
vector-only plasmid, using Lipofectamine. Approximately
1x10⁶ Spry2-HCT116 or vector-HCT116 cells were plated in
each well in 6-well plates and incubated for 16 h. Then the cells
were treated with either 20 µM of metformin, or 25 µM of
5-FU for 48 h with DMEM/F12 and 10% FBS. The cell culture
medium containing floating cells was collected. Attached cells
were rinsed with Ca²⁺ and Mg²⁺-free PBS and harvested after
incubation with 2 mM EDTA in PBS for 10 min. Floating and
attached cells were pooled and rinsed twice with PBS. Cells
were resuspended in 1X binding buffer (Axxora Platform, USA)
and incubated with FITC-conjugated Annexin V for 15 min
at room temperature in the dark, using the FITC-Annexin V
apoptosis detection kit (Roche Diagnostic). Cells were washed
twice with 1X binding buffer. The samples were immediately
analyzed on FACSCalibur flow cytometer (Becton-Dickinson
Immunocytometry System, USA) using the CellQuest Pro
Software and the WinMDI 2.9 software. Propidium iodide was
added right before the analysis of these samples.

Protein extraction and western blot analysis. HCT116 cells
were transfected with Spry2-GFP plasmid or vector-only
plasmid (control), using Lipofectamine. Twenty-four hours
after transfection, cells were treated with either controlled
medium (DMEM/F12 with 10% FBS), controlled medium
with 25 µM of 5-FU, or controlled medium with 5 µM of
metformin, for 48 h. Cells were washed twice with PBS and
lysed in 300 µl lysis buffer (20 mM Tris-HCl, pH 8.0, 100 mM
NaCl, 1 mM EDTA, 0.5% nonidet P40, 0.5% Triton X-100, 1
mM phenylmethylsulfonyl fluoride, 1 mM NaF, 1 mM
sodium orthovanadate, 1 mg each of aprotinin, leupeptin, and
pepsatin/ml) and were processed as described previously (24).
Separation of protein was performed on 10% polyacrylamide
Gels with 5% polyacrylamide stacking gel. After electrophoretic transfer (Amersham Pharmacia Biotech, USA) of protein from the SDS polyacrylamide gel to polyvinylidene difluoride membranes (Millipore, USA), the membranes were blocked with buffer containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween-20, 5% Blotto (Bio-Rad, USA) at 4°C overnight and probed with antibodies of interest. Horseradish peroxidase-conjugated anti-rabbit IgG and anti-mouse IgG were used as secondary antibodies. The position of the protein was visualized using the ECL reagent.

Cell migration/wound-healing assay. For the wound-healing assay, 48 h after transfection with Spry2-GFP or vector-only plasmid using Lipofectamine, transfected cells were plated separately overnight to achieve a confluent cell layer in a 12-well plate. Then, the medium was replaced with DMEM/F12 and 10% FBS (controlled medium) with or without metformin in the concentration of 20 mM. After making a scratch on the cell layer with a needle tip, wound-healing was visualized by monitoring the migrating cells in the gap during a 24-h post-scratch period.

Inhibition of microRNA-21 expression. The endogenous microRNA-21 (mir-21) was suppressed by transfection of the mir-21 inhibitor (Qiagen, Germany) in colon cancer cells. According to the manufacturer's protocol, 10.3 µl mir-21 inhibitor (20 µM stock) was diluted in 100 µl culture medium without serum. Twenty microliters HiPerFect Transfection Reagent (Qiagen) was added to the diluted mir-21 inhibitor. The samples were incubated for 10 min at room temperature (15-25°C) to allow the formation of transfection complexes. The complexes were added drop-wise onto the cells. The cells were incubated with the transfection complexes under their normal growth conditions.

Statistical analysis. Significance was assessed by a two-tailed Student's t-test. All data represent the average of at least three independent experiments.

Results

Spry2 enhances the cytotoxic effect of metformin and 5-FU in colon cancer cells. 5-FU is known to have an inhibitory effect on the proliferation of colon cancer and thus has become part of the chemotherapy regimen widely used in the treatment of patients with colon cancer. To explore the antiproliferative effect of Spry2, HCT116 colon cancer cells transfected with Spry2 were treated with 5-FU at the concentration of 25 µM. The growth of Spry2-HCT116 and vector-HCT116 cells was measured by the MTT assay on 4 consecutive days. HCT116 cells with ectopic expression of Spry2 showed a lower proliferation rate and 5-FU demonstrated a better cytotoxic effect on Spry2-HCT116 cells (Fig. 1A). Metformin and other AMPK activators have been shown to suppress the growth of cancer cells, such as breast cancer and colon cancer. Herein, we demonstrated that metformin at the concentration of 20 mM can inhibit the proliferation of HCT116 colon cancer cells. Overexpression of Spry2 in HCT116 cells led to a greater cytotoxic effect of metformin (Fig. 1B).

Spry2 enhances the cytotoxic effect of 5-FU or metformin through suppression of Akt and Erk activation followed by induction of cell apoptosis. We utilized flow cytometry and western blot analysis to determine the regulatory mechanism of Spry2 in promoting cancer cell death. After treatment with 5-FU, metformin, or a controlled medium for 48 h, the Annexin V stain of Spry2- and vector-HCT116 cells was measured by flow cytometry (Fig. 2A). Overexpression of Spry2 in HCT116 cells induced cell apoptosis, compared with vector-only cells treated with 5-FU (Spry2-HCT116, 4.23±0.66%; vector-HCT116, 0.62±0.012%, P<0.01). Spry2-HCT116 cells treated with 5-FU showed a higher percentage of Annexin V positive cells, compared with vector-only cells treated with 5-FU (Spry2-HCT116+5-FU, 8.91±0.33%; vector-HCT116+5-FU, 4.76±0.29%, P<0.01). On the other hand, vector-HCT116 cells treated with metformin, 20 mM, did not induce more apoptosis than
FENG et al: SPROUTY2 ENHANCES THE CYTOTOXIC EFFECT OF 5-FU AND METFORMIN IN HCT116 CELLS

vector-HCT116 cells in a controlled medium. However, after being transfected with Spry2 and treated with 20 mM of metformin, Spry2-HCT116 cells showed significantly more Annexin V positive cells compared with vector-HCT116 cells in metformin (Spry2-HCT116+metformin, 8.66±0.21%; vector-HCT116+metformin, 1.93±0.022% P<0.01) (Fig. 2B).

Using western blot analysis to demonstrate protein regulation, metformin induced PARP cleavage and decreased BCL-2 expression, leading to cell apoptosis, which corresponds to the net result of activation of AMPK and inactivation of Akt. Spry2 protein has been known to inhibit cell growth by inhibiting activation of the Ras/Raf/Erk pathway as a negative regulator. This study has demonstrated that Spry2 can also suppress the activation of the Akt pathway by inducing expression of PTEN, an important tumor suppressor (Fig. 3). These results confirmed that Spry2 can enhance the originally suppressive effect of either 5-FU or metformin in colon cancer cells.

Spry2 enhances the migration inhibition of metformin in colon cancer cells. It is known that Spry2 can inhibit tumor proliferation and migration, but there is limited information about whether treatment with metformin in Spry2 over-expressed cancer cells generates better inhibition on cell migration, so we used a wound-healing assay to test this hypothesis. The migration distance was measured by a time-lapse microscope camera within 24 h. The results showed that expression of Spry2 can inhibit migration of HCT116 cells in a controlled medium (Spry2-HCT116, 15.46±1.469 µm/h; vector-HCT116, 21.69±2.475 µm/h, P<0.05). The suppressive effect of Spry2 in cell migration of HCT116 was also demonstrated in a controlled medium with 20 mM of metformin (Spry2-HCT116+metformin, 11.17±1.587 µm/h; vector-HCT116+metformin, 15.81±1.998 µm/h, P<0.05) (Fig. 4). This implies that both strategies can work together to achieve better results in the control of tumor growth and migration.

Figure 2. Spry2 expression enhances the inhibitory effect of 5-FU and metformin through cell apoptosis in HCT116 cells. (A) Positive Annexin V cells were measured by flow cytometry. In vector-HCT116 cells, treatment with 5-FU, but not metformin, could induce cells to apoptosis by increasing the percentage of Annexin V-positive cells. Increasing the expression of Spry2 in HCT116 cells promoted apoptosis under all three conditions. (B) The bar graph demonstrates that vector-HCT116 cells treated with 5-FU increased the percentage of Annexin V positive cells from 1.6 to 4.6%, but the same effect was not shown in vector-HCT116 treated with metformin. HCT116 cells transfected with Spry2 promoted apoptosis from 1.6 to 3.8%. Spry2-HCT116 cells expressing Annexin V increased from 4.6 to 8.4% in 5-FU-containing medium and from 1.8 to 8.5% in metformin-containing medium. Results represent the mean ± SD of three experiments performed in triplicate (**P<0.01).

Figure 3. Spry2 protein increases the expression of PTEN and enhances cell apoptosis induced by 5-FU or metformin in HCT116 cells. PARP cleavage indicated activation of the apoptotic pathway and BCL-2 protein represented the index of anti-apoptosis. 5-FU can induce HCT116 cell apoptosis via activation of PARP. The phosphorylation of AMPK was activated by metformin, which led to HCT116 cell apoptosis. Ectopic expression of Spry2 protein enhanced HCT116 cell apoptosis by increasing the expression of PTEN protein. The addition of metformin in Spry2-HCT116 cells resulted in the activation of AMPK and enhancement of the AKT pathway suppressor, PTEN.
Suppression of mir-21 leads to increased expression of Spry2 and PTEN in accordance with a reduced proliferation of colon cancer cells. Our previous study had shown that expression of Spry2 is reversely correlated with expression of mir-21 in tumor samples of colon cancer patients (25). It is still unclear that mir-21 has any influence on the Spry2 induced proliferation of colon cancer cells. In colon cancer cells, HCT116, mir-21 knockdown was associated with increasing expression of Spry2 and PTEN by western blot analysis (Fig. 5A). The proliferation rate of colon cancer cells was reduced after the inhibition of mir-21 (Fig. 5B). These results correlated with the oncogenic effect of mir-21 in colon cancer as previously reported (26-28).

Discussion

There is emerging evidence indicating that Spry2 protein is downregulated in cancer cells and that the ectopic expression of Spry2 can inhibit cancer cell growth (12,13,15). Spry2 tumor suppression is possibly induced through inactivation of the Erk and Akt pathways. Resistance to primary therapy with drugs or medication is a problem requiring urgent attention in cancer treatment. More and more studies are focusing on conquering this tough problem through multi-pathway inhibition. Spry2 is a possible candidate for this strategy since it is a novel target which can suppress many RTKs, including fibroblast...
growth factor receptor and vascular epithelial growth factor receptor, and it also directly suppresses downstream effectors of RTKs, such as Ras, Raf and Erk. Spry2 protein may act as a competitive inhibitor of Erk signaling through at least two potential mechanisms. The COOH terminus of Spry2 can bind to RAF1, inhibiting kinase activity (29). Furthermore, Spry2 protein uncouples receptor tyrosine kinase signaling from the activation of Ras, possibly by sequestration of GRB2, an adaptor protein required for Ras activation (30,31). For the Akt pathway, PTEN is activated by Spry2, which leads to inactivation of Akt signaling. The downregulation of Spry2 in cancer cells may confer a proliferative advantage to tumor cells by allowing unchecked activation of the Ras/Erk pathway, which would normally be controlled by relatively higher expression levels of Spry2 in normal tissue. Several mechanisms may account for the reduced Spry2 expression in cancer cells and the association with carcinogenesis. Accordingly, in cells lines derived from non-small cell lung carcinoma, metastatic lung cancer cells tend to have a lower expression of Spry2. In addition, an inverse correlation between Spry expression and tumor grade was observed in prostate cancer (13). Actually, Spry2 has a potential antitumor property, but so far no data have shown that Spry2 can enhance other cancer treatment strategies. Our results showed that Spry2 was able to promote apoptosis in colon cancer cells and enhance the cytotoxic effect of the chemotherapeutic agent, 5-FU. 5-FU is the time-tested agent for systemic chemotherapy for colon cancer; however, the objective response rate to 5-FU is 15-20%. The therapeutic effect of 5-FU can be enhanced by combining 5-FU and other agents, such as leucovorin, oxaliplatin and irinotecan. Activation of growth factor receptor in colon cancer has been given greater attention, and specific treatment for epidermal growth factor receptor and vascular growth factor has been deployed to manage patients with metastatic colon cancer. The Spry2 mediated enhancement of the cytotoxic benefit of the 5-FU regimen implies that Spry2 may be a surrogate marker for prediction of tumor response and may play an important role in resistance to chemotherapy.

Spry2 also has the ability to generate a better effect with metformin, an AMPK activator. AMPK is known as a master negative regulator in the protein synthesis of various cells, and it has been considered as a novel therapeutic target for the treatment of cancer and other metabolic diseases (32). Recent studies on the effects of metformin on the cell signaling network have extended from the context of diabetes research to the regulation of cancer cells. The cell proliferative effects of activated AMPK via the Akt/mammalian target of rapamycin (m-TOR) or phosphatidylinositol 3-kinase (PI3K) signaling were shown in endothelial cells. In breast cancer cells, the inactivation of LKB1 by reactive lipid species was shown to inhibit the phosphorylation of AMPK, as well as the downstream Tuberous sclerosis protein (TSC)-mTOR-S6K cascade (33). Here we demonstrated metformin alone can inhibit the proliferation and migration of colon cancer cells. Cell apoptosis, demonstrated by Annexin V assay, was not increased after metformin treatment, which can be partially explained by autophagocytosis. However, the combination of Spry2-active cancer cells and metformin treatment resulted in the additional benefit of cell killing. These data support the current concept of inactivation of oncogenic pathways and suggest a the central role of Spry2 in cancer treatment (Fig. 6).

Acknowledgements

We appreciate the grant support from the National Cheng Kung University Hospital, Taiwan (research fund 2004 no. 21), the National Science Council, Taiwan (095FA09007), and the Chi-Mei Medical Center, Taiwan (research fund CLFHR9914 and CMFHR10006).
References